Clinical Pharmacology Studies Supporting Oligonucleotide Therapy Development: An Assessment of Therapies Approved and in Development Between 2012 and 2018
Synthetic nucleotides that utilize RNA‐centric pharmacology can target diseases at the RNA level, thus altering protein expression in ways previously inaccessible to small molecules and therapeutic biologics. Recognizing that the unique pharmacology of oligonucleotides may require specific considera...
Main Authors: | Hobart Rogers, Oluseyi Adeniyi, Anuradha Ramamoorthy, Samantha Bailey, Michael Pacanowski |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.12945 |
Similar Items
-
PathFX provides mechanistic insights into drug efficacy and safety for regulatory review and therapeutic development.
by: Jennifer L Wilson, et al.
Published: (2018-12-01) -
Oligonucleotide, Therapy, and Applications
Published: (2022) -
Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy
by: Yoshitsugu Aoki, et al.
Published: (2013-01-01) -
The development of BLC-2 antisense oligonucleotide therapy for non-Hodgkin's lymphoma
by: Webb, Andrew Russell
Published: (2002) -
The use of oligonucleotide aptamers in cancer therapy
by: Adrian Odrzywolski, et al.
Published: (2016-05-01)